GID.AX - GI Dynamics, Inc.

ASX - ASX Delayed Price. Currency in AUD
0.026
0.000 (0.00%)
At close: 3:52PM AEST
Stock chart is not supported by your current browser
Previous close0.026
Open0.026
Bid0.027 x 0
Ask0.035 x 0
Day's range0.026 - 0.026
52-week range0.018 - 0.065
Volume24,395
Avg. volume138,636
Market cap16.033M
Beta1.76
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
Press Releases
  • Business Wire2 months ago

    EndoBarrier Meta-Analysis Published in Diabetes Care Journal

    GI Dynamics® Inc. , a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes,” by Pichamol Jirapinyo, MD, of Brigham and Women’s ...

  • Business Wire6 months ago

    GI Dynamics Announces AUD $2.05m Private Placement and Close of First Tranche of AUD ~$1m

    GI Dynamics®, Inc. , a medical device company that is developing EndoBarrier® is pleased to announce that it has received binding commitments for a private placement of 58,780,619 CHESS Depositary Interests of the Company at an issue price of AUD $0.035 per CDI to sophisticated and professional investors in Australia, the United States, and the United Kingdom to raise approximately AUD $2.05 million ...

  • Business Wire6 months ago

    GI Dynamics, Inc. Provides 2017 Review and 2018 Business Outlook

    GI Dynamics®, Inc. , a medical device company that is developing EndoBarrier® provides shareholders with a review of 2017 activities and its 2018 business outlook.

  • Business Wire8 months ago

    GI Dynamics Announces Change to Board of Directors

    GI Dynamics®, Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America, announces today that the board of directors has received the resignation of GI Dynamics non-executive directors Anne Keating and Graham Bradley.

  • Business Wire8 months ago

    GI Dynamics to Provide Corporate Update and 2017 Third Quarter Results

    GI Dynamics® Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will provide a corporate update and discuss 2017 third quarter results to investors.

  • Business Wire8 months ago

    GI Dynamics Receives CE Certificate of Conformity Withdrawal Notice for EndoBarrier

    GI Dynamics®, Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America has received notification from its notified body SGS United Kingdom, Limited that SGS will withdraw the CE Certificate of Conformity for EndoBarrier effective 12 November 2017.